Skip to main content


We’d like to understand how you use our websites in order to improve them. Register your interest.

The actions and side effects of Anabolic Steroids in sport and social abuse

  • The Erratum to this article has been published in Andrologie 2004 14:BF03035476


Anabolic steroids (AS) derived from testosterone have both anabolic (muscle and strength enhancing) and androgenic (primary and secondary sexual) effects. Efforts to limit the androgenic while enhancing the anabolic effects have not been successful. Alterations to the structure of testosterone, so as to improve the pharmacokinetics of AS, have resulted in drugs, which are orally active, have a longer plasma half life and may be administered as depot injections. Therapeutic doses of AS produce statistically significant effects on strength and athletic performance in well-controlled scientific and clinical trials. At low, therapeutic doses, diet and an intensive training regime are equally important in producing a statistically significant increase in strength. Higher doses 6–7000mg per week are regularly administered in sport and produce the greatest increases in muscle strength erythropoiesis and lean body mass. Patterns of steroid abuse can be complex, reflecting a desire to minimise side effects, and avoid detection. AS side effects are of many types. AS increase salt and water retention leading to an expansion of the blood volume, but effects of steroids on blood pressure are equivocal and most cardiovascular side effects appear to be reversible.

Abuse of AS causes an increase in blood triglyceride and cholesterol levels and this is associated with a decline in High Density Lipoproteins (HDLs) and an increase in the Low Density (LDL) type. Though these effects are reversible they are associated with an increased risk of both acute and chronic cardiovascular pathology. The most serious irreversible anabolic steroid side effects are associated with carcinomas-mainly of the liver, prostate and kidney. Hepatic carcinomas are strongly associated with abuse of the orally active 17alpha methyl substituted steroids, which also produce a reversible jaundice. In males, anabolic steroid abuse causes suppression of LH and FSH release leading to inhibition of testosterone production often accompanied by testicular atrophy, and azoospermia. High, chronic doses of the drugs may also cause moderate to severe feminising effects in the form of gynaecomastia. Male secondary sexual characteristics are a side effect of AS abuse in women. Increased insulin resistance and elevated fasting blood glucose levels are the commonest non-gonadal endocrine side effects of AS.

AS abuse leads to contradictory, complex, behavioural, and psychiatric changes. Increased frequency of mental illness, in anabolic steroid abusers including paranoid schizophrenia, mania and depression has been reported. Physical and psychological dependency occur amongst some anabolic steroid abusers and severe psychiatric disorders can appear upon withdrawal, leading in a few cases to criminality and even suicide. We need more studies on the long-term effects of AS. The implications of the past 50 years of AS abuse will be discussed in the review.


  1. 1.

    ALDER E.M., COOK A., DAVIDSON D., WEST C. BANCROFT J.: Hormones, mood and sexuality in lactating women. Br. J. Psychiatry, 1986, 148: 74–79.

  2. 2.

    ALEN M., RAHKILA P.: Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes. Sports Med., 1988, 6: 327–332.

  3. 3.

    ARCHER J.: The influence of testosterone on human aggression. Br. J. Psychol., 1991, 82: 1–28.

  4. 4.

    BAGATELL C.J., BREMNER W.J.: Androgens in men uses and abuses. New Engl J. Med., 1996, 334: 707–714.

  5. 5.

    BAGATELL C.J., HEIMANN J.R., RIVIER J.E.: Effects of endogenous testostrone and estradiol on sexual behaviour in normal young men. J. Clin. Endocrinol. Metab., 1994, 78: 713–716.

  6. 6.

    BAHRKE M.S.: Psychological effects of endogenous testosterone and anabolic-androgenic steroids. In: Yesalis C. ed. Anabolic Steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 94–106.

  7. 7.

    BHASIN S., STORER T.W., BERMAN N. et al.: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med., 1996, 335: 1–7.

  8. 8.

    BHASIN S., WOODHOUSE L., STORER T.W.: Proof of the effect of testosterone on skeletal muscle. J. Endocrinol., 2001, 170: 27–38.

  9. 9.

    BROWER K.J.: Anabolic steroids: potential for physical and psychological dependence. In: Yesalis C. ed. Anabolic steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 279–304.

  10. 10.

    BROWER K.J.: Anabolic steroid abuse and dependence. Curr. Psychiatry Reports, 2002, 4: 377–387.

  11. 11.

    BROWER K.J., BLOW F.C., YOUNG J.P., HILL E.H.: Symptoms and correlates of anabolic steroid dependence. Br. J. Addict., 1991, 86: 759–768.

  12. 12.

    CHOI P.Y.L., POPE H.G.: Violence towards women and illicit androgen-anabolic steroid use. Ann. Clin. Psychiatry, 1994, 6: 21–25.

  13. 13.

    COHEN J.C., HICKMAN R.: Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J. Clin. Endocrinol. Metab., 1987, 64: 960–963.

  14. 14.

    COPELAND J., PETERS R., DILLON P.: Anabolic-androgenic steroid dependence in a woman. Austr. N.Z. J. Psychiatry, 1998, 32: 589–591.

  15. 15.

    COSTILL D.L., PEARSON D.R., FINK W.J.: Anabolic steroid use among athletes. Changes in HDC-C levels. Phys. Sports Med., 1984, 12: 113–117.

  16. 16.

    DALY R.C., SU T-P., SCHMIDT P.J., PICKAR D., MURPHY D.L., RUBINOW D.R.: Cerebrospinal fluid and behavioural changes after methyltestosterone administration. Arch. Gen. Psychiatry, 2001, 58: 172–177.

  17. 17.

    DALY R.C., SU T-P., SCHMIDT P.J., PAGLIARO M., PICKAR D., RUBINOW D.R.: Neuroendocrine and behavioural effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology, 2003, 28: 317–331.

  18. 18.

    EBENBICHLER C.F., STURM W., GANZER H. et al.: Flow-mediated, endothelium dependent vasodilation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis, 2001, 158: 483–490.

  19. 19.

    ELASHOFF J.D., JACKNOW A.D., SHAIN S.G., BRAUNSTEIN G.D.: Effects of anabolic-androgenic steroids on muscular strength. Ann. Int. Med., 1991, 115: 387–393.

  20. 20.

    EVANS N.A.: Gym and tonic: a profile of 100 male steroid users. Br. J. Sports Med., 1997, 31: 54–58.

  21. 21.

    FORBES G.B.: The effect of anabolic steroids on lean body mass. The dose response curve. Metabolism, 1985, 34: 571–573.

  22. 22.

    FREED D.L.J., BANKS A.J., LONGSON D., BURLEY D.M.: Anabolic steroids in athletes: cross-over double blind trial in weightlifters. Br. Med. J., 1975, 2: 471–473.

  23. 23.

    FRIEDL K.E., YESALIS C.E.: Self-treatment of gynaecomastia in body builders who use anabolic steroids. Phys. Sports Med., 1989, 17: 67–79.

  24. 24.

    GEORGE A.J.: Drugs in Sport—chemists v cheats-a score draw! Chem. Rev., 4: 10–14.

  25. 25.

    GEORGE A.J.: Anabolic steroids. In: Mottram D.R. ed. Drugs in Sprot 3rd Edition. London, E. & F. Spon, 2003, 138–188.

  26. 26.

    GILL G.V.: Anabolic steroid induced hypogonadism treated with human chorionic gonadotrophins. Postgrad. Med. J., 1998, 74: 45–46.

  27. 27.

    GLAZER G.: Arthrogenic effects of anabolic steroids on serum lipid levels. Arch. Int. Med., 1991, 151: 1925–1933.

  28. 28.

    GOLDMAN B.: Death in the locker room: Steroids and sports. London, Century Publishing, 1984.

  29. 29.

    GUO Z., BENTEN W.P., KRUCKEN J., WUNDERLICH F.: Nongenomic testosterone calcium signalling: genomic actions in androgen receptor-free macrophages. J. Biol. Chem., 2002, 277: 29600–29607.

  30. 30.

    GUSTAVSSON G., TRASKMAN-BENDZ L., DEE HIGLEY J., WESTRIN Å.: CSF testosterone in 43 male suicide attempters. Europ. Neuropsychopharmacology, 2003, 13: 105–109.

  31. 31.

    HARTGENS D., VAN STRAATEN H., FIDELDIJ S., RIETJENS G., KEIZER H.A., KUIPERS H.: Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. Europ. J. Appl. Physiol., 2002, 86: 233–239.

  32. 32.

    HAUPT H.A., ROVERE G.D.: Anabolic steroids: A review of the literature. Am. J. Sports Med., 1984, 12: 469–484.

  33. 33.

    HEALD A.H., IVISON F., ANDERSON S.G., CRUICKSHANK K., LAING I., GIBSON J.M.: Significant ethnic variation in total and free testosterone concentration. Clin. Endocrinol., 2003, 58: 262–266.

  34. 34.

    HERVEY G.R., KNIBBS A.V., BURKINSHAW L. et al.: Effects of methandione on the performance and body composition of man undergoing athletic training. Clin. Sci., 1981, 60: 457–461.

  35. 35.

    HOBBS C.J., JONES R.E., PLYMATE S.R.: Nandrolone, a 19-nortestosterone, enhances insulin dependent glucose uptake in normal men. J. Endocrinol. Metab., 1996, 81: 1582–1585.

  36. 36.

    HOLMA P.K.: Effects of an anabolic steroid (methandienone) on spermatogenesis. Contraception, 1979, 15: 151–162.

  37. 37.

    JAROW J.P., LIPSCHULTZ L.I.: Anabolic steroid induced hypogonadotrophic hypogonadism. Am. J. Sports Med., 1990, 18: 429–431.

  38. 38.

    KADI F., ERIKSSON A., HOLMNER S., BUTLER-BROWNE G., THORNHILL L.E.: Cellullar adaptation of the trapezius muscle in strength trained athletes. Histochem. Cell Biol., 1999, 111: 189–195.

  39. 39.

    KADI F., BONNERUND P., ERIKSSON A., THORNELL L.E.: The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem. Cell Biol., 2000, 113: 25–29.

  40. 40.

    KASHKLIN K.B., KLEBER H.D.: Hooked on hormones? An anabolic steroid addiction hypothesis. J. Amer. Med. Assoc., 1989, 262: 3166–3170.

  41. 41.

    KOURI E.M., LUKAS S.E., POPE H.G., OLIVA P.S.: Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend., 1995, 40: 73–79.

  42. 42.

    KUHN C.M.: Anabolic Steroids. Endocrinol. Rev., 2002, 13: 411–434.

  43. 43.

    KUTSCHER E.C., LUND B.C., PERRY P.J.: Anabolic Steroids —A review for the clinician. Sports Med., 2002, 32: 285–296.

  44. 44.

    LUBELL A.: Does steroid abuse cause-or excuse-violence? Phys. Sport Med., 1989, 17: 176–185.

  45. 45.

    LUKAS S.E.: Current perspectives on anabolic-androgenic steroid abuse. Trends Pharmacol. Sci., 1993, 14: 61–68.

  46. 46.

    LOMBARDO J.A., HICKSON P.C., LAMB D.R.: Anabolic/androgenic steroids and growth hormone. In: Lamb D.R., Williams M.H. eds. Perspectives in Exercise Science and Sports Medicine, Vol. 4: Ergogenics-Enhancement of Performance in Exercise and Sport. New York, Brown and Benchmark, 1991, 249–278.

  47. 47.

    MCINDOE J.H., PERRY P.J., YATES W.R. et al.: Testosterone suppression of the HPT axis. J. Invest. Med., 1997, 45: 441–447.

  48. 48.

    MILLAR A.P.: Licit steroid use—hope for the future. Br. J. Sports Med., 1994, 28: 79–83.

  49. 49.

    MOTTRAM D.R., GEORGE A.J.: Anabolic steroids. Clin. Endocrinol. Metab., 2000, 14: 55–69.

  50. 50.

    NELSON K.A., WHITE J.S.: Androgen receptor CAG repeats and prostate cancer. Am. J. Epidemiol., 2002, 155: 883–890.

  51. 51.

    NIEMINEN M.S., RAMO M.P., VIITASALO M. et al.: Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Europ. Heart J., 1996, 17: 1576–1583.

  52. 52.

    OLIVARDIA R., POPE H.G., HUDSON J.L.: Muscle dysmorphia in male weightlifters: a case control study. Am. J. Psychiatry, 2000, 157: 1291–1296.

  53. 53.

    PARSINNEN M., KINJALA U., VARTIAINEN E., SARNA S., SEPPALA T.: Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int. J. Sports Med., 2000, 21: 225–227.

  54. 54.

    PARSSINEN M., SEPPALA T.: Steroid use and long-term health risks in former athletes. Sports Med., 2002, 32: 83–94.

  55. 55.

    POPE H.G., KATZ D.L.: Psychiatric and medical effects of anabolic-androgenic steroid use. Arch. Gen. Psychiat., 1994, 51: 375–382.

  56. 56.

    POPE H.G., GRUBER A.J., CHOI P., OLIVARDIA R., PHILLIPS K.A.: Muscle dysmorphia. Psychosomatics, 1997, 38: 548–557.

  57. 57.

    POPE H.G., KOURI E.M., HUDSON J.I.: Effects of supraphysiological doses of testosterone on mood and aggressionin normal men. Arch. Gen. Psychiatry, 2000, 57: 133–140.

  58. 58.

    POPE H.G., COHANE G.H., KANAYAMA G., SIEGEL A.J., HUDSON J.I.: Testosterone gel supplementation for men with refractory depression: a randomised placebo-controlled trial. Am. J. Psychiatry (in press).

  59. 59.

    PORCERELLI J.H., SANDLER B.A.: Narcissism and empathy in steroid users Ann. J. Psychiatry, 1995, 152: 1672–1674.

  60. 60.

    RABKIN J.G., WAGNER G.J., RABKIN R.: A double blind, placebo controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry, 2000, 57: 141–147.

  61. 61.

    RAGLIN J.S.: Psychological factors in sport performance. Sports Med., 2001, 31: 875–890.

  62. 62.

    ROCKHOLD R.W.: Cardiovascular toxicity of anabolic steroids. Ann. Rev. Pharmac. Tox., 1993, 33: 497–520.

  63. 63.

    ROGOL A.D., YESALIS C.E.: Anabolic-androgenic steroids and athletes: What are the issues? J. Endocrinol. Metab., 1992, 74: 465–469.

  64. 64.

    RUBINOW D.R., SCHMIDT P.J.: Androgens, brain and behaviour. Am. J. Psychiatry, 1996, 153: 974–984.

  65. 65.

    RYAN A.J.: Anabolic steroids are fool’s gold. Fed. Proc., 1981, 40: 2682–2688.

  66. 66.

    SACHS B.D., LEIPHEIMER R.E.: Rapid effect of testosterone on striated muscle activity in rats. Neuroendocrinology, 1988, 48: 453–458.

  67. 67.

    SEIDMANN S.N., RABKIN J.G.: Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J. Affect. Disord., 1998, 48: 157–161.

  68. 68.

    SHEFFIELD-MOORE M., URBAN R.J., WOLF S.E. et al.: Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J. Clin. Endocrinol. Metab., 1999, 84: 2705–2711.

  69. 69.

    STIMAC D., MILLI S., DINTINJANA R.D., KOVAC D., RISTI S.: Androgenic/Anabolic steroid induced toxic hepatitis. J. Clin. Gastroenterol., 2002, 35: 350–352.

  70. 70.

    STORER T.W., MAGLIANO L., WOODHOUSE L. et al.: Testosterone dose-dependently increases maximal voluntary strength and leg-power, but does not affect fatigability or specific tension. J. Endocrinol. Metab., 2003, 88: 1478–1485.

  71. 71.

    STREET C., ANTONIO J., CUDLIPP D.: Androgen use by athletes: A re-evaluation of the health risks. Canad. J. Appl. Physiol., 1996, 21: 421–440.

  72. 72.

    SULLIVAN M.L., MARTINEZ C.M., GENNIS C. et al.: The cardiac toxicity of anabolic steroids. Prog. Cardiovasc. Dis., 1998, 41: 1–15.

  73. 73.

    THIBLIN I., LINDQUIST O., RAJS J.: Cause and manner of death among abusers of anabolic androgenic steroids. J. Forensic Sci., 2000, 45: 16–23.

  74. 74.

    TUREK P.J., WILLIAMS R.H., GILLBRAUCH J.H. et al.: The reversibility of anabolic steroid induced azoospermia. J. Urol., 1995, 153: 1628–1630.

  75. 75.

    UEKI M., OKANA M.: Doping with naturally occurring steroids. J. Toxicol. Toxin. Rev., 1999, 18: 177–195.

  76. 76.

    VAN BREDA E., KEIZER H.A., KUIPERS H., WOLFFEN-BUTTEL B.H.R.: Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int. J. Sports Med., 2003, 24: 195–196.

  77. 77.

    WILLIAMSON P.J., YOUNG A.H.: Psychiatric effects of androgenic and anabolic-androgenic steroid abuse in men: a brief review of the literature. J. Psychopharmac., 1992, 6: 20–26.

  78. 78.

    WILSON J.D.: Androgen abuse by athletes. Endocrinol. Rev., 1988, 9: 181–199.

  79. 79.

    WOODHOUSE L.J., REISZ-PORSZASZ S., JAVANBAKHT M. et al.: Development of models to predict anabolic response to testosterone administration in healthy young men. Am. J. Physiol., 2003, 284: 1009–1017.

  80. 80.

    WRIGHT J.E.: Anabolic steroids and athletics. Exerc. Sport Sci. Rev., 1980, 8: 149–202.

  81. 81.

    WRIGHT F., BRICOUT V., DOUKANI A., BONGINI M.: Nandrolone et nor-stéroïdes: substances endogènes ou xénobiotiques? Sci. Sports, 2000, 15: 111–124.

  82. 82.

    WROBLEWSKA A.M.: Androgenic-anabolic steroids and body dysmorphia in young men. J. Psychosom. Res., 1997, 42: 225–234.

  83. 83.

    WU F.C.W.: Endocrine agents of anabolic steroids. Clin. Chem., 1997, 43: 1289–1292.

  84. 84.

    YANG P., JONES B.L., HENDERSON L.P.: Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABAa receptors. Neuropharmacology, 2002, 43: 619–633.

  85. 85.

    YATES W.R., PERRY P.J., MACINDOE J., HOLMAN T. ELLINGRAD V.: Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol. Psychiatry, 1999, 45: 254–260.

  86. 86.

    YESALIS C., COURSON S., WRIGHT J.: History of anabolic steroid use in sport and exercise. In: Yesalis C. ed. Anabolic Steroids in sport and exercise. Champaign Il, Human Kinetics Publishers, 2000: 54–56.

Download references

Author information



Corresponding author

Correspondence to Alan James George.

Additional information

Communication au XIXo Congrès de la Société d’Andrologie de Langue Française, Genève, 12–14 decembre 2002.

An erratum to this article is available at

Rights and permissions

Reprints and Permissions

About this article

Cite this article

George, A.J. The actions and side effects of Anabolic Steroids in sport and social abuse. Androl. 13, 354 (2003).

Download citation

Key Words

  • anabolic steroids
  • androgenic anabolic steroids
  • testosterone
  • side-effects
  • sport
  • athletics
  • abuse
  • pathology
  • dependency
  • review
  • reversible
  • chronic